2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14557A
    Pimavanserin hemitartrate 706782-28-7 99.91%
    Pimavanserin (ACP-103) hemitartrate is a potent 5-HT 2A receptor inverse agonist with pIC50 and pKi of 8.73 and 9.3, respectively.
    Pimavanserin hemitartrate
  • HY-157839
    PROTAC α-synuclein degrader 6 3032208-24-2 99.28%
    PROTAC α-synuclein degrader 6 (compound T3) is a PROTAC degrader of α-synuclein and tau, with EC50 of 1.57 μM and 4.09 μM, respectively. PROTAC α-synuclein degrader 6 plays an important role in neurodegenerative diseases (NDs) research (Blue:ubiquitin E3 ligase cereblon ligand (HY-14658), Black: linker (HY-128803); Pink: Ligand for target protein (HY-151035)).
    PROTAC α-synuclein degrader 6
  • HY-159115
    ART26.12 2766800-24-0 99.57%
    ART26.12 is a potent, selective and orally active inhibitor of FABP5. ART26.12 can regulate lipid metabolism and activate cannabinoid receptors. ART26.12 has analgesic effects and can be used in the research of diseases such as peripheral neuropathy and psoriasis.
    ART26.12
  • HY-32329A
    Setiptiline maleate 85650-57-3 99.94%
    Setiptiline maleate (MO-8282 maleate) is a serotonin receptor antagonist. Setiptiline maleate is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline maleate acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine.
    Setiptiline maleate
  • HY-B0118A
    Vecuronium bromide 50700-72-6 ≥98.0%
    Vecuronium (ORG NC 45) bromide is a non-depolarizing neuromuscular blocking agent that also acts as a nicotinic acetylcholine receptor (nAChR) inhibitor, a muscle relaxant, and can be used for pre-surgical anesthesia.
    Vecuronium bromide
  • HY-B0552A
    Dibucaine hydrochloride 61-12-1 99.97%
    Dibucaine hydrochloride (Cinchocaine hydrochloride) is a sodium channel inhibitor. Dibucaine hydrochloride is a potent SChE inhibitor.
    Dibucaine hydrochloride
  • HY-P0203B
    β-CGRP (mouse) 99.77%
    β-CGRP (mouse) is a calcitonin gene-related peptide that induces vasodilation. β-CGRP (mouse) can be utilized in cardiovascular, pro-inflammatory, migraine and metabolic research.
    β-CGRP (mouse)
  • HY-P1422A
    Spadin TFA 99.73%
    Spadin TFA, a natural peptide derived from a propeptide released in blood, is a potent TREK-1 channel blocker with an IC50 value of 10 nM. Spadin TFA enhances dorsal raphe nucleus 5-HT neurotransmission in mice and induces hippocampal CREB activation and neurogenesis. Spadin TFA can be used for antidepressant research.
    Spadin TFA
  • HY-P3400A
    LP17 TFA 99.85%
    LP17 (LQVTDSGLYRCVIYHPP) TFA is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LP17 TFA substantially alleviates ischemia-induced infarction and neuronal injury. LP17 TFA can get access into brain and block TREM-1.
    LP17 TFA
  • HY-107625A
    SNAP 94847 hydrochloride 1781934-47-1 99.90%
    SNAP 94847 hydrochloride is a novel, high affinity selective melanin-concentrating hormonereceptor1 (MCHR1) antagonist with (Ki= 2.2 nM, Kd=530 pM), it displays >80-fold and >500-fold selectivity over MCHα1A and MCHD2 receptors respectively. SNAP 94847 hydrochloride binds with high affinity to the mouse and rat MCHR1 with minimal cross-reactivity to other GPCR, ion channels, enzymes, and transporters.
    SNAP 94847 hydrochloride
  • HY-B0762S1
    Acetyl-L-carnitine-d3-1 hydrochloride 362049-62-5 ≥98.0%
    Acetyl-L-carnitine-d3-1 (O-Acetyl-L-carnitine-d3-1) hydrochloride is the deuterium labeled Acetyl-L-carnitine hydrochloride (HY-B0762). Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression.
    Acetyl-L-carnitine-d3-1 hydrochloride
  • HY-N0830S5
    Palmitic acid-d3 75736-53-7 ≥98.0%
    Palmitic acid-d3 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-d3
  • HY-W004049
    3-Hydroxybenzoic acid 99-06-9 99.89%
    3-Hydroxybenzoic acid is an orally active endogenous metabolite. 3-Hydroxybenzoic acid is an agonist for GPR81 and GPR109A. 3-Hydroxybenzoic acid acts as stress response desensitizers. 3-Hydroxybenzoic acid can be used for anti-inflammatory and analgesic study.
    3-Hydroxybenzoic acid
  • HY-W008350
    (+)-Sparteine 492-08-0 ≥98.0%
    (+)-Sparteine is a natural alkaloid acting as a ganglionic blocking agent. (+)-Sparteine competitively blocks nicotinic ACh receptor in the neurons.
    (+)-Sparteine
  • HY-B1274
    Cinromide 58473-74-8 99.83%
    Cinromide is an anticonvulsant agent. Cinromide inhibits epithelial neutral amino acid transporter B0AT1 (SLC6A19) with an IC50 of 0.5 μM.
    Cinromide
  • HY-P1389
    Neuropeptide S (human) 412938-67-1 99.71%
    Neuropeptide S human, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human can be used for Alzheimer's disease (AD) research.
    Neuropeptide S (human)
  • HY-W011235
    Norfluoxetine hydrochloride 57226-68-3 99.58%
    Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity.
    Norfluoxetine hydrochloride
  • HY-100456
    ZL006 1181226-02-7 99.23%
    ZL006 is a potent inhibitor of nNOS/PSD-95 interaction, and inhibits NMDA receptor-mediated NO synthesis.
    ZL006
  • HY-10233
    Gaboxadol hydrochloride 85118-33-8 ≥98.0%
    Gaboxadol hydrochloride (Lu 02-030 hydrochloride) is a potent agonist of the GABAA receptor and an antagonist of GABAC receptors (IC50=25 μM). Gaboxadol hydrochloride displays a partial agonist efficacy on subunit α1β2γ2 with an ED50 value of 143 μM, a full agonist efficacy at α5 subunit (ED50=28-129 μM) and a superagonist efficacy at α4β3δ (ED50=6 μM). Gaboxadol hydrochloride is a non-opioid agent.
    Gaboxadol hydrochloride
  • HY-100406
    (S)-MCPG 150145-89-4 99.02%
    (S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371). (S)-MCPG can be used for the study of the function of mGluRs in spatial learning.
    (S)-MCPG
Cat. No. Product Name / Synonyms Application Reactivity